Back

NNC6019-0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Amyloidosis and aortic stenosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Incidence and factors associated with de novo atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis
Doctor C. Fumagalli (Naples, IT)
Abstract Slides
Presentation thumbnail
Transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience
Doctor L. Scudeler (Turin, IT)
Abstract Slides
Presentation thumbnail
Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment.
Doctor M. Morioka (Kumamoto, JP)
Abstract Slides
Presentation thumbnail
Valve disease in cardiac amyloidosis: an echocardiographic score
Doctor A. Aimo (Pisa, IT)
Abstract Slides
Presentation thumbnail
Global longitudinal strain and quantitative sensory testing in pre-symptomatic patients with mutation for transthyretin amyloidosis
Associate Professor M. Losi (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Amyloidosis and aortic stenosis

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources